Open AccessEmpagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
Author(s) -
Yihai Liu,
Mingyue Wu,
Baojun Xu,
Kang Lee
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s309427
Subject(s) - empagliflozin , inflammation , endocrinology , medicine , lesion , diabetes mellitus , type 2 diabetes , pharmacology , pathology
Recent clinical studies have revealed that sodium glucose co-transporter 2 inhibitors (SGLT2i) reduced cardiovascular events in type 2 diabetes. Here, we investigated whether empagliflozin, as a kind of SGLT2i, could alleviate atherosclerosis progression in non-diabetic mice.